Weekly shot shows promise for boosting growth in kids with dwarfism
Disease control
Completed
This study tested a weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely improves growth rate over a year compared to a placebo. After the blinded phase, all children could receive…
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 15, 2026 11:58 UTC